| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy
|
Wheler, J.J.
|
|
|
24 |
3 |
p. 838-842
|
article
|
| 2 |
A clinical–biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status
|
Bria, E.
|
|
|
24 |
3 |
p. 693-701
|
article
|
| 3 |
Adolescents with acute lymphoblastic leukemia treated at pediatric versus adult hospitals
|
Pole, J.D.
|
|
|
24 |
3 |
p. 801-806
|
article
|
| 4 |
Alcohol drinking and all cancer mortality: a meta-analysis
|
Jin, M.
|
|
|
24 |
3 |
p. 807-816
|
article
|
| 5 |
A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma
|
Turati, F.
|
|
|
24 |
3 |
p. 609-617
|
article
|
| 6 |
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG
|
Banerjee, S.
|
|
|
24 |
3 |
p. 679-687
|
article
|
| 7 |
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation
|
Seiwert, T.Y.
|
|
|
24 |
3 |
p. 769-776
|
article
|
| 8 |
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck †
|
Abdul Razak, A.R.
|
|
|
24 |
3 |
p. 761-769
|
article
|
| 9 |
ARIX: A randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer
|
Simcock, R.
|
|
|
24 |
3 |
p. 776-783
|
article
|
| 10 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report †
|
Okines, A.F.C.
|
|
|
24 |
3 |
p. 702-709
|
article
|
| 11 |
Biology matters: the clinical impact of single-receptor discordance on breast cancer
|
Farolfi, A.
|
|
|
24 |
3 |
p. 851
|
article
|
| 12 |
Clinical complete response in locally advanced rectal cancer: can we offer a wait-and-see policy?
|
Hernández-García, I.
|
|
|
24 |
3 |
p. 853
|
article
|
| 13 |
Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients
|
Bertucci, F.
|
|
|
24 |
3 |
p. 625-632
|
article
|
| 14 |
Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients
|
Romero, A.
|
|
|
24 |
3 |
p. 655-661
|
article
|
| 15 |
Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients
|
Ilie, M.
|
|
|
24 |
3 |
p. 742-748
|
article
|
| 16 |
Early development of the metabolic syndrome after chemotherapy for testicular cancer
|
de Haas, E.C.
|
|
|
24 |
3 |
p. 749-755
|
article
|
| 17 |
Editorial board
|
|
|
|
24 |
3 |
p. ii-iii
|
article
|
| 18 |
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
|
Dubsky, P.
|
|
|
24 |
3 |
p. 640-647
|
article
|
| 19 |
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
|
Ghielmini, M.
|
|
|
24 |
3 |
p. 561-576
|
article
|
| 20 |
European cancer mortality predictions for the year 2013
|
Malvezzi, M.
|
|
|
24 |
3 |
p. 792-800
|
article
|
| 21 |
Female fertility loss and preservation: threats and opportunities
|
Salama, M.
|
|
|
24 |
3 |
p. 598-608
|
article
|
| 22 |
From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)
|
Couraud, S.
|
|
|
24 |
3 |
p. 586-597
|
article
|
| 23 |
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
|
Thomas, A.
|
|
|
24 |
3 |
p. 577-585
|
article
|
| 24 |
Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
|
Warneke, V.S.
|
|
|
24 |
3 |
p. 725-733
|
article
|
| 25 |
Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane
|
Guerrero, A.
|
|
|
24 |
3 |
p. 674-679
|
article
|
| 26 |
Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients
|
Seong, S.J.
|
|
|
24 |
3 |
p. 756-760
|
article
|
| 27 |
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07
|
Helbling, D.
|
|
|
24 |
3 |
p. 718-725
|
article
|
| 28 |
Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE †
|
Thariat, J.
|
|
|
24 |
3 |
p. 824-831
|
article
|
| 29 |
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
|
Eatock, M.M.
|
|
|
24 |
3 |
p. 710-718
|
article
|
| 30 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors
|
Macaulay, V.M.
|
|
|
24 |
3 |
p. 784-791
|
article
|
| 31 |
Preoperative PET/CT in early-stage breast cancer: is the TNM classification enough?
|
Gilardi, L.
|
|
|
24 |
3 |
p. 852
|
article
|
| 32 |
Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse
|
Cancello, G.
|
|
|
24 |
3 |
p. 661-668
|
article
|
| 33 |
Prospective analysis of vitamin D and endometrial cancer risk
|
Liu, J.J.
|
|
|
24 |
3 |
p. 687-692
|
article
|
| 34 |
Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall
|
Gronchi, A.
|
|
|
24 |
3 |
p. 817-823
|
article
|
| 35 |
Reply to ‘preoperative PET/CT in early-stage breast cancer: is the TNM classification enough?’
|
Bernsdorf, M.
|
|
|
24 |
3 |
p. 852-853
|
article
|
| 36 |
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy
|
Denkert, C.
|
|
|
24 |
3 |
p. 632-639
|
article
|
| 37 |
Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma?
|
Le Péchoux, C.
|
|
|
24 |
3 |
p. 832-837
|
article
|
| 38 |
Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer
|
Lyratzopoulos, G.
|
|
|
24 |
3 |
p. 843-850
|
article
|
| 39 |
Specific PPAR gamma agonists may have different effects on cancer incidence
|
Bambury, R.M.
|
|
|
24 |
3 |
p. 854
|
article
|
| 40 |
Table of Contents
|
|
|
|
24 |
3 |
p. iv-vii
|
article
|
| 41 |
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
|
Eiermann, W.
|
|
|
24 |
3 |
p. 618-624
|
article
|
| 42 |
The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms
|
Caponi, S.
|
|
|
24 |
3 |
p. 734-741
|
article
|
| 43 |
The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy
|
Gobardhan, P.D.
|
|
|
24 |
3 |
p. 668-673
|
article
|
| 44 |
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement †
|
Azim Jr, H.A.
|
|
|
24 |
3 |
p. 647-654
|
article
|
Journal description